The DOI matches its Crossref record; 126 of the 129 references it cites were found in a registry or an index.
The Evolving Future of PCSK9 Inhibitors
Open accessAbstract
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups. Clinical trials with PCSK9 inhibitors have demonstrated reductions in atherosclerotic cardiovascular disease events, particularly in patients with recent acute coronary syndrome, multivessel coronary artery disease, or peripheral arterial disease. Commonly observed profound reductions in LDL-C to levels <25 mg/dl have been accompanied by even lower rates of atherosclerotic cardiovascular disease events, thus supporting the concept that there may be no lower limit for LDL-C. Aggressive LDL-C lowering with fully human PCSK9 monoclonal antibodies has been accompanied by a safety profile that has been very favorable. On the basis of clinical trial evidence, LDL lowering with PCSK9 inhibitors is recommended for high-risk patients with LDL-C levels ≥70 mg/dl on maximally tolerated oral therapies including statins and/or ezetimibe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Patients with receptor-negative HoFH derive minimal benefit from PCSK9-targeted therapy, whereas receptor-defective HoFH and heterozygous FH (HeFH) patients exhibit clinically meaningful LDL-C reductions [84].”
In the citing paper
“This concept is likely to be relevant to humans because dramatic reductions in plasma LDL-cholesterol levels lead to the regression of even advanced atherosclerotic lesions, and plaque regression is accompanied by lower rates of atherosclerotic cardiovascular disease events210,211.”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Flagged first, then by citations
3 of the 129 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Kastelein, 2015, ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, Eur Heart J, 36, 2996
- Hopkins, 2015, Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody, Circ Cardiovasc Genet, 8, 823, 10.1161/CIRCGENETICS.115.001129 · DOI
- Institute for Clinical and Economic Review posts updated economic analyses for PCSK9 inhibitor evolocumab, finds less favorable cost-effectiveness [press release]. Boston, MA: ICER; September 11, 2017. Available at: https://icer-review.org/announcements/pcsk9-neu/. Accessed April 4, 2018.
- Institute for Clinical and Economic Review updates value-based price benchmark for alirocumab, a PCSK9 inhibitor for treatment of high cholesterol [press release]. Boston, MA: ICER; March 10, 2018. Available at: https://icer-review.org/announcements/alirocumab-prelim-evidence-update/. Accessed April 4, 2018.
Cited by
Sorted by citations
Items 101–200 of 273
Likozar, A. R., & Šebeštjen, M. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.07.001 · Cited by 12
Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
Danilov, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000498 · Cited by 12
Novel therapies for familial hypercholesterolemia
Mohamed, F., Seedat, F., & Raal, F. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000590 · Cited by 13
Rosenson, R. S., Tate, A., Mar, P., Grushko, O. G., Chen, Q., & Goonewardena, S. N. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117529 · Cited by 13
Self-citationJianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 14
Wang, Z., Bao, Q., Song, X., Song, H., Wei, S., Lv, J., Wang, F., & An, J. (2022) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2022.0011 · Cited by 11
Nishikido, T., & Ray, K. K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14851 · Cited by 11
ANGPLT3 in cardio-metabolic disorders
Su, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06248-6 · Cited by 11
Zyryanov, S. K., & Butranova, O. I. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5271 · Cited by 10
Lee, P. C., Jung, I., Thussu, S., Patel, V., Wagoner, R., Burks, K. H., Amrute, J., Elenbaas, J. S., Kang, C. J., Young, E. P., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110104 · Cited by 11
Homocysteine concentration in coronary artery disease and severity of coronary lesions
Luo, Z., Tang, K., Huang, G., Wang, X., Zhou, S., Dai, D., Yang, H., & Jiang, W. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18474 · Cited by 10
Lohoff, F. W. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy087 · Cited by 10
Investigational drugs in phase II clinical trials for acute coronary syndromes
Rout, A., Sukhi, A., Chaudhary, R., Bliden, K. P., Tantry, U. S., & Gurbel, P. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708324 · Cited by 11
Lipid Disorders in Children and Adolescents
Daniels, S. R., & Couch, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00025-7 · Cited by 10
Gene and cell therapy approaches for familial hypercholesterolemia: An update.
Parsamanesh, N., Kooshkaki, O., Siami, H., Santos, R., Jamialahmadi, T., & Sahebkar, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103470 · Cited by 10
CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis
Gu, B., Li, M., Li, D., & Huang, K. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10587-7 · Cited by 13
Disrupted Lipid Metabolism Aggravates Ischemic Brain Injury: Targeting FDFT1 for Stroke Therapy
Yuan, J., Liao, Y.-S., Zhang, T.-C., Liu, S., Ruan, M.-M., Yang, T., Sun, S.-Q., Xu, L., Xie, X., & Zhao, L. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05217-5 · Cited by 9
A closed-loop cholesterol shunt controlling experimental dyslipidemia
Unal, G., Xie, Y., & Fussenegger, M. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.08.011 · Cited by 9
Wang, S. C., Kaur, G., Schulman‐Marcus, J., Purga, S. L., Mookherjee, S., Miller, C., Sidhu, M. S., & Rosenson, R. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07085-8 · Cited by 9
Self-citationVitamin D3 suppresses the cholesterol homeostasis pathway in patient‐derived glioma cell lines
Yuan, R., Zhang, W., You, Y., Cui, G., Gao, Z., Wang, X., & Chen, J. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13679 · Cited by 8
Fatima, E., Qureshi, Z. A., Khanzada, M., Safi, A., Rehman, O. U., & Altaf, F. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00654-4 · Cited by 8
Aisha Siddiq, A., Abduldileep, S., Rao, S. J. A., Singam, S. S. R., & Martin, A. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119697 · Cited by 8
Theodorou, A., Papagiannopoulou, G., Akrivaki, A., Fanouraki, S., Moschovos, C., Papadopoulou, Μ., Palaiodimou, L., Merkouri, F., Melanis, K., Salakou, S., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70175 · Cited by 8
RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
Saboo, B., Agarwal, S., Makkar, B. M., Chawla, R., Ghosh, S. K., Viswanathan, V., Gupta, S., Kumar, C. V., Maheshwari, A., Sreenivasamurthy, L., et al. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01063-6 · Cited by 9
Dahle, N., Ärnlöv, J., Leppert, J., & Hedberg, P. (2023) · Vascular Medicine · doi:10.1177/1358863x231161655 · Cited by 9
Proteomic analysis of 92 circulating proteins and their effects in cardiometabolic diseases
Carland, C., Png, G., Mälarstig, A., Kho, P. F., Gustafsson, S., Michaëlsson, K., Lind, L., Tsafantakis, E., Karaleftheri, M., Dedoussis, G. V., et al. (2023) · Clinical Proteomics · doi:10.1186/s12014-023-09421-0 · Cited by 8
Lin, P., Wu, Y., Lin, C., Yeh, H., Chang, W., Charng, M., Huang, P., Lin, C., Lin, T., Lin, W.-W., et al. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63789 · Cited by 8
Bellino, M., Galasso, G., Silverio, A., Tedeschi, M., Formisano, C., Romei, S., Esposito, L., Cancro, F. P., Vassallo, M. G., Accarino, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082922 · Cited by 10
Gherasie, F.-A., Popescu, M. R., & Bartos, D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060944 · Cited by 8
Gianazza, E., Macchi, C., Banfi, C., & Ruscica, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1191303 · Cited by 10
PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
Chen, D.-Q., Xu, W., Xiao, K.-Y., Que, Z.-Q., Feng, J., Sun, N.-K., Cai, D.-X., & Rui, G. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07674-w · Cited by 7
Liu, S., Lin, H. R., Zhang, K., Zhou, Q., & Shen, Y. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01620-7 · Cited by 7
He, J., Dai, Y., Xu, F., Huang, X., Gao, Y., Liu, L., Zhang, W., & Liu, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140826 · Cited by 7
Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
Nejabat, M., Hadizadeh, F., Almahmeed, W., & Sahebkar, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104316 · Cited by 7
Genetics of coronary artery disease
Wu, A., JianKun, L. I. U., Zhao, Y., Khan, A. H., LiYong, L. I. A. O., & Tian, X. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0347 · Cited by 6
Li, L., & Ma, X. (2023) · European journal of medical research · doi:10.1186/s40001-023-01050-5 · Cited by 7
Mei, J., Fu, X., Liu, Z., Zhang, L., Geng, Z., Xie, W., Yu, M., Wang, Y., Zhao, J., Zhang, X., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04186-2 · Cited by 6
Gurevitz, C., Zadok, O. I. B., Leshem‐Lev, D., Hodeda, L., Rotholz, A., Kornowski, R., & Eisen, A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100896 · Cited by 6
Sun, J., Liu, H.-R., Zhang, W., Shi, J., Wu, Q., Xu, R., & Zhu, Y. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12796 · Cited by 7
Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction
Yaghoubi, D., & Sallam, T. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.07.002 · Cited by 6
Zhao, Q., Sun, S., Yue, J., Zhang, Y., Hou, S., Qu, X., 冼慧敏, Luo, X., & Qu, X. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s417481 · Cited by 6
Anderson, H., Sweeney, C. A., Perry, R. M., Vaquero, J., & Ison, H. E. (2020) · Medical Science Educator · doi:10.1007/s40670-019-00872-5 · Cited by 6
Ahn, J., Chae, H., Pel, P., Kim, Y., Choi, Y. H., Kim, J., & Chin, Y. (2021) · Biomolecules · doi:10.3390/biom11030463 · Cited by 7
Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and AtherosclerosisPreprint
Zhou, Z., Zhu, J., Yeh, C., Meliton, A. Y., Wu, D., Huang, R., Shentu, T., Ray, A. G., Wiseman, D., Budina, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.09.632179 · Cited by 6
Yang, L., Xu, M., Gao, X., Liu, J., Zhang, D., Zhang, Z., Ye, Z., Wen, J., & Liu, P. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508292 · Cited by 6
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5
“Patients with receptor-negative HoFH derive minimal benefit from PCSK9-targeted therapy, whereas receptor-defective HoFH and heterozygous FH (HeFH) patients exhibit clinically meaningful LDL-C reductions [84].”
Chen, Y., Wang, G., Jiang, Y., Qian, K., Liu, Y., Qiu, C., & Huang, P. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157120 · Cited by 5
Qureshi, Z. A., Khanzada, M., Safi, A., Fatima, E., Altaf, F., & Vittorio, T. J. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001945 · Cited by 5
Cholesterol reduction by immunization with a PCSK9 mimic
Zhang, B., Chuang, G., Biju, A., Biner, D. W., Cheng, J., Wang, Y., Bao, S., Chao, C. W., Lei, H., Liu, T. W. B., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114285 · Cited by 5
Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
Tang, H., Li, X., Wang, F., Liu, H., Zhang, X., Liu, B., & Wang, B. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04347-1 · Cited by 5
Diagnostik und Therapie von statinassoziierten Muskelsymptomen
Kassner, U., Grunwald, S. A., Spira, D., Buchmann, N., Bobbert, T., Gazzerro, E., Hollstein, T., Spuler, S., & Steinhagen‐Thiessen, E. (2021) · Der Internist · doi:10.1007/s00108-021-01059-0 · Cited by 5
Randall, Z. D., Brouillard, A. M., Deych, E., & Rich, M. W. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100196 · Cited by 5
Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
Imaralu, O. E., Narasimhulu, C. A., Singal, P. K., & Singla, D. K. (2023) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2023-0223 · Cited by 5
Suzuki, T., Tsurane, K., Umemoto, T., Sasano, T., Ushiki, E., Fudono, A., Hirose, A., Sekiguchi, M., & Miyasaka, N. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15813 · Cited by 5
Liang, L., Chung, S. I., Guon, T., Park, K. H., Lee, J., & Park, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02842-x · Cited by 5
Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs
Zuin, M., Corsini, A., Valle, C. D., Rosa, C. D., Maloberti, A., Mojoli, M., Rizzo, M., Ciccirillo, F., Madrid, A., Riccio, C., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae076 · Cited by 5
Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry
Briani, F., Sani, E., Venturi, G., Bacchion, F., Balzano, S., Battocchio, M., D'Elia, K., Frigo, G. M., Licchelli, L., Lupo, A., et al. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07749-3 · Cited by 6
Looking Back at US Pharmacy’s Past to Help Discern Its Future
Shcherbakova, N., & Desselle, S. P. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020911085 · Cited by 5
Effect of alirocumab on cataracts in patients with acute coronary syndromes
Suc, G., Schwartz, G. G., Goodman, S. G., Jukema, J. W., Manvelian, G. Z., Poulouin, Y., Pordy, R. C., Scemama, M., Szarek, M. J., Steg, P. G., et al. (2023) · BMC Ophthalmology · doi:10.1186/s12886-023-03012-1 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Grassi, G. M., Pinto, R. D., Rosei, C. A., Agnoletti, D., Borghi, C., Cicero, A. F. G., Ciuceis, C. D., Desideri, G., Grassi, D., Muiesan, M. L., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00501-6 · Cited by 8
Optimizing Cholesterol Management Improves the Benefits of Percutaneous Coronary Intervention
Rosenson, R. S., Colantonio, L. D., & Goonewardena, S. N. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.050 · Cited by 5
Self-citationAssociation between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study
Liu, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1353848 · Cited by 5
Paryani, M., Gupta, N., Jain, S. K., & Butani, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03826-4 · Cited by 4
Zhang, Y., Chai, Z., Chen, M., Li, S., Zhuang, W., Hu, W. W., & Chen, M. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100046 · Cited by 5
Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors
Shaw, P. B. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88606 · Cited by 4
Shi, W., Xu, Y., Zhou, L., Wang, W., Huang, W., & Zhou, B. (2024) · Medicine · doi:10.1097/md.0000000000037416 · Cited by 4
Xu, L., Wang, L., Wang, Y., Wang, Y., Jiang, Y., Du, P., Cheng, J., Zhang, C., Wang, R., Jiao, T., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1408760 · Cited by 4
Liu, D., Zhang, J., Zhang, X., Jiang, F., Wu, Y., Yang, B., Li, X., Fan, X., Han, L., Sun, Y., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1454918 · Cited by 4
Gil-Núñez, A., Masjuán, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F. F., Arenillas, J. F., & Palacio, E. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.11.014 · Cited by 4
Zhang, X., Liu, Q., Zhang, H., Tan, C., Zhu, Q., Chen, S., Du, Y., Yang, H., Li, Q., Xu, C., et al. (2022) · Molecular Genetics and Genomics · doi:10.1007/s00438-022-01892-4 · Cited by 4
Familial Hypercholesterolemia: Update and Review
Chacon-Camacho, O. F., Pozo‐Molina, G., Méndez-Catalá, C. F., Reyes‐Reali, J., Méndez-Cruz, R., & Zenteno, J. C. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210208212148 · Cited by 4
Gim, D. H., Choi, I. Y., Ki, Y.-J., Kim, H. K., Kim, S. S., Park, K. H., Song, H., & Choi, D.-H. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.363 · Cited by 3
Inhibition of PCSK9 with polypurine reverse hoogsteen hairpins: A novel gene therapy approach
López-Aguilar, E., Pacheco-Velázquez, S. C., Busquets, M.-A., Hay, J., Mueller, P. A., Fazio, S., Ciudad, C. J., Noé, V., & Pamir, N. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116976 · Cited by 3
Self-citationChoi, J., & Gwon, J. (2025) · Vascular Specialist International · doi:10.5758/vsi.250043 · Cited by 5
Ábel, T., Benczúr, B., & Csajbókné, É. C. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03965-w · Cited by 3
Review of Lipid-Lowering Therapy in Women from Reproductive to Postmenopausal Years
Witting, C. S., Devareddy, A., & Rodríguez, F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305183 · Cited by 5
Gupta, J., & Gupta, R. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467216666221202144813 · Cited by 3
Can one overcome “unhealthy genes”?
Lazarte, J., & Hegele, R. A. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0099-2 · Cited by 3
Self-citationGil-Núñez, A., Masjuán, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F. F., Arenillas, J. F., & Palacio, E. (2021) · Neurología · doi:10.1016/j.nrl.2020.11.006 · Cited by 3
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
Canonico, M. E., Hess, C. N., & Cannon, C. P. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01112-3 · Cited by 3
Self-citationSmall molecule inhibitors of PCSK9. SAR investigations of head and amine groups
Aspnes, G. E., Coffey, S. B., Darout, E., Dechert‐Schmitt, A. R., Dullea, R., Kamlet, A. S., Limberakis, C., Londregan, A. T., McClure, K. F., Menhaji‐Klotz, E., et al. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129394 · Cited by 3
Roles of PCSK9 in the Pathogenesis of Periodontal Disease
Khosrojerdi, M., Reiner, Ž., Vatanparast, N., Jamialahmadi, T., Kesharwani, P., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230809100021 · Cited by 3
Malvandi, A. M., Canclini, L., Alliaj, A., Magni, P., Zambon, A., & Catapano, A. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1801628 · Cited by 3
Familial hypercholesterolaemia and emerging therapeutics
Farias, F. I., Kim, S. M., & Shapiro, M. D. (2023) · Heart · doi:10.1136/heartjnl-2022-321917 · Cited by 3
A tip of the CAP1 to cholesterol metabolism
Dron, J. S., & Hegele, R. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz771 · Cited by 3
Self-citationAnalysis of Adherence to anti-PCSK9 Antibody Therapy among Patients from Italy
Mongiello, P., Petti, R., Ciaccia, A., Morgese, M. G., & Lombardi, R. (2023) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x23666230810094738 · Cited by 2
Tu, K.-C., Chang, W., Lin, H.-W., Lin, P., Wu, Y., Lin, C., Yeh, H., Charng, M., Huang, P., Lin, T., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02431-8 · Cited by 2
Lu, H., Wang, S., Huang, W., Fan, F. S., & Wei, J. C. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04332-3 · Cited by 2
Zhang, M., Jiang, Y., Lu, P., Shen, Z., Gao, X. Y., & Wang, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c11879 · Cited by 2
Wu, J., Lin, Y. M., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M. H., Yu, T., & Lai, C.-C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1709009 · Cited by 3
Kulshreshtha, A., & Bhatnagar, S. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153224 · Cited by 2
Wu, J.-Y., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · QJM · doi:10.1093/qjmed/hcag235 · Cited by 2
PCSK9 and lipid metabolism and atherosclerosis: animal models
Getz, G. S., & Reardon, C. A. (2021) · Vessel Plus · doi:10.20517/2574-1209.2020.70 · Cited by 3
Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift
Maranta, F., Cianfanelli, L., Gaspardone, C., Rizza, V., Grippo, R., Ambrosetti, M., & Cianflone, D. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.05.050 · Cited by 2
Crosstalk between skeletal muscle ratio and cholesterol metabolism disorders: a cross-section study
Wang, Y., Hu, J., Shen, H., Liu, C., & Yang, L. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01660-y · Cited by 2
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 4
Self-citationRecent progress in anti-atherosclerosis strategies and prospective therapeutic targets
Wang, Z., He, X., Bai, H., Feng, D., Qu, Y., Zhang, Y., Lee, R. J., & Sun, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126122 · Cited by 4
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88608 · Cited by 2
Dayspring, T. D., & Pokrywka, G. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_13 · Cited by 2
Metadata
- Authors
- Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P.
- Affiliations
- Mount Sinai Hospital (US)
- Western University (CA)
- Oregon Health & Science University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Rosenson, Robert S.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 72
- Issue
- 3
- Pages
- 314-329
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2848978533
- Cited by
- 264
- References
- 129
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 34 · 2023: 47 · 2022: 31 · 2021: 35 · 2020: 27 · 2019: 26 · 2018: 7
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- American College of Cardiology Foundation
- Regeneron Pharmaceuticals
- Kowa Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- PCSK9 inhibitors, PCSK9, LDL cholesterol lowering, monoclonal antibodies, atherosclerotic cardiovascular disease, acute coronary syndrome, multivessel coronary artery disease, peripheral arterial disease, hypercholesterolemia
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Humans, Hypercholesterolemia, Cholesterol, LDL, Treatment Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
